Alvotech (ALVO)
NASDAQ: ALVO · Real-Time Price · USD
7.97
-0.27 (-3.28%)
Oct 13, 2025, 4:00 PM EDT - Market closed
Alvotech Revenue
Alvotech had revenue of $173.34M in the quarter ending June 30, 2025, a decrease of -12.79%. This brings the company's revenue in the last twelve months to $562.48M, up 82.19% year-over-year. In the year 2024, Alvotech had annual revenue of $491.98M with 426.84% growth.
Revenue (ttm)
$562.48M
Revenue Growth
+82.19%
P/S Ratio
4.03
Revenue / Employee
$555,808
Employees
1,012
Market Cap
2.49B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 491.98M | 398.60M | 426.84% |
| Dec 31, 2023 | 93.38M | 8.37M | 9.84% |
| Dec 31, 2022 | 85.02M | 45.33M | 114.23% |
| Dec 31, 2021 | 39.68M | -29.77M | -42.86% |
| Dec 31, 2020 | 69.45M | -13.23M | -16.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ALVO News
- 7 days ago - My Top 5 Biotech Stocks Big Pharma Could Buy Next - Seeking Alpha
- 7 days ago - European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency - GlobeNewsWire
- 21 days ago - European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva® - GlobeNewsWire
- 21 days ago - European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner - GlobeNewsWire
- 24 days ago - Alvotech Announces Marketing Approval in Japan of Three New Biosimilars - GlobeNewsWire
- 4 weeks ago - Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York - GlobeNewsWire
- 7 weeks ago - Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea® - GlobeNewsWire